Efficacy of prophylactic lamivudine to prevent hepatitis B virus reactivation in B-cell lymphoma treated with rituximab-containing chemotherapy

被引:26
作者
Wang, Yin-Hua [1 ]
Fan, Lei [1 ]
Wang, Li [1 ]
Zhang, Run [1 ]
Xu, Ji [1 ]
Fang, Cheng [1 ]
Li, Jian-Yong [1 ]
Xu, Wei [1 ]
机构
[1] Nanjing Med Univ, Jiangsu Prov Hosp, Affiliated Hosp 1, Dept Hematol, Nanjing 210029, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
Hepatitis B virus; Lamivudine; Rituximab; B-cell lymphoma; NON-HODGKINS-LYMPHOMA; CHRONIC LYMPHOCYTIC-LEUKEMIA; HEMATOLOGIC MALIGNANCIES; FOLLICULAR LYMPHOMA; FATAL REACTIVATION; SURFACE-ANTIGEN; INFECTION; PATIENT; THERAPY; CHOP;
D O I
10.1007/s00520-012-1656-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Reactivation of hepatitis B virus (HBV) is a common complication in patients with HBV infection who receive cytotoxic chemotherapy. In rituximab-containing chemotherapy for B-cell lymphoma, severe hepatitis due to HBV reactivation occurred. The aim of this study is to estimate the effect of prophylactic lamivudine on the risk of HBV reactivation in patients with HBV infection who receive rituximab-containing chemotherapy. In this study, HBV markers and liver function tests were monitored in 268 consecutive patients with B-cell lymphoma, who received rituximab-containing chemotherapy between January 2008 and November 2011. Sixty-nine patients (25.7 %) with either chronic HBV infection or past HBV infection received prophylaxis with lamivudine 100 mg daily by oral intake. In the HBsAg-positive group, six (6/38) patients developed hepatitis, only one of which was attributed to HBV reactivation. In the HBsAg-negative and HBcAb-positive group, two (2/31) patients developed hepatitis, none of which was attributed to HBV reactivation. These results support that prophylactic lamivudine can prevent HBV reactivation for B-cell lymphoma with HBV infection who was receiving rituximab-containing chemotherapy.
引用
收藏
页码:1265 / 1271
页数:7
相关论文
共 36 条
[1]
American Society of Clinical Oncology Provisional Clinical Opinion: Chronic Hepatitis B Virus Infection Screening in Patients Receiving Cytotoxic Chemotherapy for Treatment of Malignant Diseases [J].
Artz, Andrew S. ;
Somerfield, Mark R. ;
Feld, Jordan J. ;
Giusti, Andrew F. ;
Kramer, Barnett S. ;
Sabichi, Anita L. ;
Zon, Robin T. ;
Wong, Sandra L. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3199-3202
[2]
Bermúdez A, 2000, HAEMATOLOGICA, V85, P894
[3]
Hepatitis B reactivation induced by Rituximab maintenance therapy for lymphoma [J].
Cho, Chun-Hung ;
Hwang, Wen-Lee ;
Cheng, Shao-Bin ;
Lee, Teng-Yu ;
Teng, Chien-Lin .
ANNALS OF HEMATOLOGY, 2011, 90 (01) :111-112
[4]
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].
Coiffier, B ;
Lepage, E ;
Brière, J ;
Herbrecht, R ;
Tilly, H ;
Bouabdallah, R ;
Morel, P ;
Van den Neste, E ;
Salles, G ;
Gaulard, P ;
Reyes, F ;
Gisselbrecht, C .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242
[5]
Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP [J].
Dai, MS ;
Chao, TY ;
Kao, WY ;
Shyu, RY ;
Liu, TM .
ANNALS OF HEMATOLOGY, 2004, 83 (12) :769-774
[6]
Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. [J].
Dervite, I ;
Hober, D ;
Morel, P .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (01) :68-69
[7]
GALBRAITH RM, 1975, LANCET, V2, P528
[8]
Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab [J].
Goldberg, SL ;
Pecora, AL ;
Alter, RS ;
Kroll, MS ;
Rowley, SD ;
Waintraub, SE ;
Imrit, K ;
Preti, RA .
BLOOD, 2002, 99 (04) :1486-1488
[9]
Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab [J].
Hamaki, T ;
Kami, M ;
Kusumi, E ;
Ueyama, J ;
Miyakoshi, S ;
Morinaga, S ;
Mutou, Y .
AMERICAN JOURNAL OF HEMATOLOGY, 2001, 68 (04) :292-294
[10]
The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma [J].
He, Yi-Fu ;
Li, Yu-Hong ;
Wang, Feng-Hua ;
Jiang, Wen-Qi ;
Xu, Rui-Hua ;
Sun, Xiao-Fei ;
Xia, Zhong-Jun ;
Huang, Hui-Qiang ;
Lin, Tong-Yu ;
Zhang, Li ;
Bao, Shi-Ping ;
He, You-Jian ;
Guan, Zhong-zhen .
ANNALS OF HEMATOLOGY, 2008, 87 (06) :481-485